Design Therapeutics (DSGN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.31, -1.62% vs the prior close of $10.48.
- Volume 854.55K shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DSGN dips 1.6% to $10.31. Closed at $10.31, -1.62% vs the prior close of $10.48. Day range $10.16–$10.50, opened at $10.46.
DSGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DSGN dips 1.6% to $10.31
- Closed at $10.31, -1.62% vs the prior close of $10.48. Day range $10.16–$10.50, opened at $10.46.
- Volume was 854.55K shares, 1.3x its 50-day average of 637.28K.
- Price is -23.6% vs its 50-day average ($13.49) and -14.8% vs its 200-day average ($12.10).
- 52-week range $5.28–$17.25; today's close sits at 42% of that range, 40.2% below the 52-week high.
Oct 15, 2026 — DSGN jumps 7.7% to $10.48
- Closed at $10.48, +7.71% vs the prior close of $9.73. Day range $9.81–$10.61, opened at $9.81.
- Volume was 503.90K shares, 0.8x its 50-day average of 636.64K.
- Price is -22.7% vs its 50-day average ($13.56) and -13.3% vs its 200-day average ($12.09).
- 52-week range $5.28–$17.25; today's close sits at 43% of that range, 39.2% below the 52-week high.
Oct 14, 2026 — DSGN dips 0.5% to $9.73, a 6-month low, 3 down days in a row
- Closed at $9.73, -0.51% vs the prior close of $9.78. Day range $9.48–$9.99, opened at $9.65.
- Volume was 1.05M shares, 1.7x its 50-day average of 621.18K.
- Price is -28.6% vs its 50-day average ($13.62) and -19.5% vs its 200-day average ($12.09).
- 52-week range $5.28–$17.25; today's close sits at 37% of that range, 43.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — DSGN slides 10.4% to $9.78, a 6-month low
- Closed at $9.78, -10.36% vs the prior close of $10.91. Day range $9.48–$10.98, opened at $10.84.
- Volume was 727.40K shares, 1.2x its 50-day average of 616.19K.
- Price is -28.6% vs its 50-day average ($13.69) and -19.1% vs its 200-day average ($12.09).
- 52-week range $5.28–$17.25; today's close sits at 38% of that range, 43.3% below the 52-week high.
Oct 12, 2026 — DSGN slides 6.4% to $10.91, a 3-month low
- Closed at $10.91, -6.35% vs the prior close of $11.65. Day range $10.89–$11.81, opened at $11.67.
- Volume was 304.30K shares, 0.5x its 50-day average of 622.67K — lighter than usual.
- Price is -20.6% vs its 50-day average ($13.75) and -9.7% vs its 200-day average ($12.09).
- 52-week range $5.28–$17.25; today's close sits at 47% of that range, 36.8% below the 52-week high.
Oct 9, 2026 — DSGN rises 1.4% to $11.65
- Closed at $11.65, +1.39% vs the prior close of $11.49. Day range $11.40–$11.92, opened at $11.47.
- Volume was 356.60K shares, 0.6x its 50-day average of 626.33K — lighter than usual.
- Price is -15.4% vs its 50-day average ($13.77) and -3.6% vs its 200-day average ($12.08).
- 52-week range $5.28–$17.25; today's close sits at 53% of that range, 32.5% below the 52-week high.
Oct 8, 2026 — DSGN dips 1.7% to $11.49, a 3-month low, 3 down days in a row
- Closed at $11.49, -1.71% vs the prior close of $11.69. Day range $11.14–$11.83, opened at $11.55.
- Volume was 674.80K shares, 1.1x its 50-day average of 623.93K.
- Price is -16.7% vs its 50-day average ($13.79) and -4.8% vs its 200-day average ($12.07).
- 52-week range $5.28–$17.25; today's close sits at 52% of that range, 33.4% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — DSGN dips 2.3% to $11.69, a 1-month low
- Closed at $11.69, -2.34% vs the prior close of $11.97. Day range $11.57–$12.06, opened at $11.82.
- Volume was 344.50K shares, 0.5x its 50-day average of 626.82K — lighter than usual.
- Price is -15.3% vs its 50-day average ($13.80) and -3.1% vs its 200-day average ($12.06).
- 52-week range $5.28–$17.25; today's close sits at 54% of that range, 32.2% below the 52-week high.
Oct 6, 2026 — DSGN slides 3.6% to $11.97, a 1-month low
- Closed at $11.97, -3.62% vs the prior close of $12.42. Day range $11.78–$12.52, opened at $12.41.
- Volume was 642.50K shares, 1.0x its 50-day average of 620.43K.
- Price is -13.3% vs its 50-day average ($13.81) and -0.7% vs its 200-day average ($12.05).
- 52-week range $5.28–$17.25; today's close sits at 56% of that range, 30.6% below the 52-week high.
Oct 5, 2026 — DSGN rises 0.6% to $12.42
- Closed at $12.42, +0.65% vs the prior close of $12.34. Day range $12.03–$12.68, opened at $12.37.
- Volume was 680.80K shares, 1.1x its 50-day average of 615.16K.
- Price is -10.0% vs its 50-day average ($13.81) and +3.2% vs its 200-day average ($12.04).
- 52-week range $5.28–$17.25; today's close sits at 60% of that range, 28.0% below the 52-week high.
Oct 2, 2026 — DSGN rises 0.8% to $12.34
- Closed at $12.34, +0.82% vs the prior close of $12.24. Day range $12.24–$12.94, opened at $12.62.
- Volume was 565.80K shares, 0.9x its 50-day average of 611.91K.
- Price is -10.5% vs its 50-day average ($13.79) and +2.6% vs its 200-day average ($12.02).
- 52-week range $5.28–$17.25; today's close sits at 59% of that range, 28.5% below the 52-week high.
DSGN latest news & SEC filings
Every SEC filing by or about DSGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$20.16M (prior year -$19.08M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.32 (prior year -$0.34) (loss narrowed vs Jun 30, 2025)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade DSGN
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: Apr 28, 2026, Mar 9, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.98% (largest 10.4%).
- Liquidity: about 568.61K shares (≈$5.86M) trade per day on average.
- 52-week position: $10.31 vs a range of $5.28–$17.25 (42% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 10-Q Aug 3, 2026; 8-K Aug 3, 2026; 8-K Jun 11, 2026.
- Share count: 62.58M shares outstanding (Jul 29, 2026), +9.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
DSGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.46 | 10.50 | 10.16 | 10.31 | 854.55K |
| Oct 15, 2026 | 9.81 | 10.61 | 9.81 | 10.48 | 503.90K |
| Oct 14, 2026 | 9.65 | 9.99 | 9.48 | 9.73 | 1.05M |
| Oct 13, 2026 | 10.84 | 10.98 | 9.48 | 9.78 | 727.40K |
| Oct 12, 2026 | 11.67 | 11.81 | 10.89 | 10.91 | 304.30K |
| Oct 9, 2026 | 11.47 | 11.92 | 11.40 | 11.65 | 356.60K |
| Oct 8, 2026 | 11.55 | 11.83 | 11.14 | 11.49 | 674.80K |
| Oct 7, 2026 | 11.82 | 12.06 | 11.57 | 11.69 | 344.50K |
| Oct 6, 2026 | 12.41 | 12.52 | 11.78 | 11.97 | 642.50K |
| Oct 5, 2026 | 12.37 | 12.68 | 12.03 | 12.42 | 680.80K |
| Oct 2, 2026 | 12.62 | 12.94 | 12.24 | 12.34 | 565.80K |
| Oct 1, 2026 | 12.50 | 12.82 | 12.21 | 12.24 | 346.60K |
| Sep 30, 2026 | 12.70 | 12.82 | 12.40 | 12.57 | 589.50K |
| Sep 29, 2026 | 12.51 | 12.75 | 12.02 | 12.62 | 655.80K |
| Sep 28, 2026 | 12.09 | 12.49 | 11.85 | 12.36 | 433.10K |
| Sep 25, 2026 | 12.29 | 12.51 | 11.97 | 12.12 | 434.50K |
| Sep 24, 2026 | 12.32 | 12.32 | 11.83 | 12.24 | 459.70K |
| Sep 23, 2026 | 13.07 | 13.24 | 12.12 | 12.36 | 738.30K |
| Sep 22, 2026 | 12.41 | 13.30 | 12.40 | 13.16 | 506.50K |
| Sep 21, 2026 | 12.35 | 12.65 | 12.15 | 12.55 | 506.40K |
About Design Therapeutics
Design Therapeutics (DSGN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CARLSBAD, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1807120.
DSGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Heather A. Berger | Director | Jun 11, 2026 |
| Simeon George | Director | Jun 11, 2026 |
| Justin D. Gover | Director | Jun 11, 2026 |
| Rodney W Lappe | Director | Jun 11, 2026 |
| John P. Schmid | Director | Jun 11, 2026 |
| Pratik Shah | President, CEO and Chairperson | Jan 5, 2026 |
| David Shapiro | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Julie Burgess | Chief Accounting Officer | Jan 5, 2026 |
| Sean Jeffries | Chief Operating Officer | Jan 5, 2026 |
| Pratik Shah | President, CEO and Chairperson | Jan 5, 2026 |
| Chris Storgard | Chief Medical Officer | Jan 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
DSGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-69.79M | -1.22 | $-54.36M |
| Dec 31, 2024 | — | $-49.59M | -0.88 | $-43.10M |
| Dec 31, 2023 | — | $-66.86M | -1.19 | $-58.56M |
| Dec 31, 2022 | — | $-63.31M | -1.14 | $-51.32M |
| Dec 31, 2021 | — | $-35.53M | -0.77 | $-29.38M |
Latest balance sheet: total assets $215.13M, total liabilities $13.27M, cash $12.91M (as of Jun 30, 2026).
DSGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $12.76 |
| Apr 28, 2026 | 8-K Item 2.02 (results) | $12.81 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $10.37 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $6.55 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $3.97 |
| May 7, 2025 | 8-K Item 2.02 (results) | $3.33 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $4.87 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $5.79 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DSGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.